Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound

Brian P. Mead, Panagiotis Mastorakos, Jung Soo Suk, Alexander L. Klibanov, Justin S Hanes, Richard J. Price

Research output: Contribution to journalArticle

Abstract

Gene therapy holds promise for the treatment of many pathologies of the central nervous system (CNS), including brain tumors and neurodegenerative diseases. However, the delivery of systemically administered gene carriers to the CNS is hindered by both the blood-brain barrier (BBB) and the nanoporous and electrostatically charged brain extracelluar matrix (ECM), which acts as a steric and adhesive barrier. We have previously shown that these physiological barriers may be overcome by, respectively, opening the BBB with MR image-guided focused ultrasound (FUS) and microbubbles and using highly compact "brain penetrating" nanoparticles (BPN) coated with a dense polyethylene glycol corona that prevents adhesion to ECM components. Here, we tested whether this combined approach could be utilized to deliver systemically administered DNA-bearing BPN (DNA-BPN) across the BBB and mediate localized, robust, and sustained transgene expression in the rat brain. Systemically administered DNA-BPN delivered through the BBB with FUS led to dose-dependent transgene expression only in the FUS-treated region that was evident as early as 24 h post administration and lasted for at least 28 days. In the FUS-treated region ~ 42% of all cells, including neurons and astrocytes, were transfected, while less than 6% were transfected in the contralateral non-FUS treated hemisphere. Importantly, this was achieved without any sign of toxicity or astrocyte activation. We conclude that the image-guided delivery of DNA-BPN with FUS and microbubbles constitutes a safe and non-invasive strategy for targeted gene therapy to the brain.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalJournal of Controlled Release
Volume223
DOIs
StatePublished - Feb 10 2016

Fingerprint

Nanoparticles
Blood-Brain Barrier
DNA
Brain
Microbubbles
Genes
Transgenes
Astrocytes
Genetic Therapy
Central Nervous System
Brain Diseases
Brain Neoplasms
Neurodegenerative Diseases
Adhesives
Pathology
Neurons
Therapeutics

Keywords

  • Blood-brain barrier
  • CNS diseases
  • Focused ultrasound
  • Non-viral gene delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound. / Mead, Brian P.; Mastorakos, Panagiotis; Suk, Jung Soo; Klibanov, Alexander L.; Hanes, Justin S; Price, Richard J.

In: Journal of Controlled Release, Vol. 223, 10.02.2016, p. 109-117.

Research output: Contribution to journalArticle

Mead, Brian P. ; Mastorakos, Panagiotis ; Suk, Jung Soo ; Klibanov, Alexander L. ; Hanes, Justin S ; Price, Richard J. / Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound. In: Journal of Controlled Release. 2016 ; Vol. 223. pp. 109-117.
@article{420496f5a6ef4151bf7c835f59577123,
title = "Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound",
abstract = "Gene therapy holds promise for the treatment of many pathologies of the central nervous system (CNS), including brain tumors and neurodegenerative diseases. However, the delivery of systemically administered gene carriers to the CNS is hindered by both the blood-brain barrier (BBB) and the nanoporous and electrostatically charged brain extracelluar matrix (ECM), which acts as a steric and adhesive barrier. We have previously shown that these physiological barriers may be overcome by, respectively, opening the BBB with MR image-guided focused ultrasound (FUS) and microbubbles and using highly compact {"}brain penetrating{"} nanoparticles (BPN) coated with a dense polyethylene glycol corona that prevents adhesion to ECM components. Here, we tested whether this combined approach could be utilized to deliver systemically administered DNA-bearing BPN (DNA-BPN) across the BBB and mediate localized, robust, and sustained transgene expression in the rat brain. Systemically administered DNA-BPN delivered through the BBB with FUS led to dose-dependent transgene expression only in the FUS-treated region that was evident as early as 24 h post administration and lasted for at least 28 days. In the FUS-treated region ~ 42{\%} of all cells, including neurons and astrocytes, were transfected, while less than 6{\%} were transfected in the contralateral non-FUS treated hemisphere. Importantly, this was achieved without any sign of toxicity or astrocyte activation. We conclude that the image-guided delivery of DNA-BPN with FUS and microbubbles constitutes a safe and non-invasive strategy for targeted gene therapy to the brain.",
keywords = "Blood-brain barrier, CNS diseases, Focused ultrasound, Non-viral gene delivery",
author = "Mead, {Brian P.} and Panagiotis Mastorakos and Suk, {Jung Soo} and Klibanov, {Alexander L.} and Hanes, {Justin S} and Price, {Richard J.}",
year = "2016",
month = "2",
day = "10",
doi = "10.1016/j.jconrel.2015.12.034",
language = "English (US)",
volume = "223",
pages = "109--117",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound

AU - Mead, Brian P.

AU - Mastorakos, Panagiotis

AU - Suk, Jung Soo

AU - Klibanov, Alexander L.

AU - Hanes, Justin S

AU - Price, Richard J.

PY - 2016/2/10

Y1 - 2016/2/10

N2 - Gene therapy holds promise for the treatment of many pathologies of the central nervous system (CNS), including brain tumors and neurodegenerative diseases. However, the delivery of systemically administered gene carriers to the CNS is hindered by both the blood-brain barrier (BBB) and the nanoporous and electrostatically charged brain extracelluar matrix (ECM), which acts as a steric and adhesive barrier. We have previously shown that these physiological barriers may be overcome by, respectively, opening the BBB with MR image-guided focused ultrasound (FUS) and microbubbles and using highly compact "brain penetrating" nanoparticles (BPN) coated with a dense polyethylene glycol corona that prevents adhesion to ECM components. Here, we tested whether this combined approach could be utilized to deliver systemically administered DNA-bearing BPN (DNA-BPN) across the BBB and mediate localized, robust, and sustained transgene expression in the rat brain. Systemically administered DNA-BPN delivered through the BBB with FUS led to dose-dependent transgene expression only in the FUS-treated region that was evident as early as 24 h post administration and lasted for at least 28 days. In the FUS-treated region ~ 42% of all cells, including neurons and astrocytes, were transfected, while less than 6% were transfected in the contralateral non-FUS treated hemisphere. Importantly, this was achieved without any sign of toxicity or astrocyte activation. We conclude that the image-guided delivery of DNA-BPN with FUS and microbubbles constitutes a safe and non-invasive strategy for targeted gene therapy to the brain.

AB - Gene therapy holds promise for the treatment of many pathologies of the central nervous system (CNS), including brain tumors and neurodegenerative diseases. However, the delivery of systemically administered gene carriers to the CNS is hindered by both the blood-brain barrier (BBB) and the nanoporous and electrostatically charged brain extracelluar matrix (ECM), which acts as a steric and adhesive barrier. We have previously shown that these physiological barriers may be overcome by, respectively, opening the BBB with MR image-guided focused ultrasound (FUS) and microbubbles and using highly compact "brain penetrating" nanoparticles (BPN) coated with a dense polyethylene glycol corona that prevents adhesion to ECM components. Here, we tested whether this combined approach could be utilized to deliver systemically administered DNA-bearing BPN (DNA-BPN) across the BBB and mediate localized, robust, and sustained transgene expression in the rat brain. Systemically administered DNA-BPN delivered through the BBB with FUS led to dose-dependent transgene expression only in the FUS-treated region that was evident as early as 24 h post administration and lasted for at least 28 days. In the FUS-treated region ~ 42% of all cells, including neurons and astrocytes, were transfected, while less than 6% were transfected in the contralateral non-FUS treated hemisphere. Importantly, this was achieved without any sign of toxicity or astrocyte activation. We conclude that the image-guided delivery of DNA-BPN with FUS and microbubbles constitutes a safe and non-invasive strategy for targeted gene therapy to the brain.

KW - Blood-brain barrier

KW - CNS diseases

KW - Focused ultrasound

KW - Non-viral gene delivery

UR - http://www.scopus.com/inward/record.url?scp=84953230426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953230426&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2015.12.034

DO - 10.1016/j.jconrel.2015.12.034

M3 - Article

VL - 223

SP - 109

EP - 117

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -